JPRN-jRCT2031230181招募中4 期
The phase 4 study of the tacrolimus ointment 0.03% in Infant and toddler patients with Atopic dermatitis -Long-term study
ishiura Tomoyuki0 个研究点目标入组 20 人开始时间: 2023年6月25日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 6month old 至 < 2age old（—）
- 性别
- All
入选标准
- •Patients with mild or higher atopic dermatitis aged between 6 months and 2 years.
排除标准
- •- medical history and/or concomitant disease of malignancy, serious allegies, allegy to tacrolimus or skin hypersensitivity to topical medicinal products.
- •- serious complication of any cardiac, hepatic, renal, pulmonary, hematological disorder etc, which is considered inappropriate to participate in the trial by investigators.
研究者
相似试验
招募中
3 期
A Phase 3 clinical study to determine the pharmacokinetics, safety and efficacy of rVWF:rFVIII and rVWF in the treatment of bleeding episodes in subjects diagnosed with von Willebrand diseaseCoagulation disorderHereditary deficiency of Von Willebrand Factor in blood1006447710005330NL-OMON38008Baxter4
进行中（未招募）
1 期
Clinical trial to confirm and expand information on absorption, distribution, elimination in the body, efficacy, tolerability and safety of a new drug in patients with impaired immune system.Primary immunodeficiencyEUCTR2013-003877-87-HUOctapharma Pharmazeutika Prod.Ges.m.b.H64
进行中（未招募）
1 期
Clinical trial to confirm and expand information on absorption, distribution, elimination in the body, efficacy, tolerability and safety of a new drug in patients with impaired immune system.Primary immunodeficiencyEUCTR2013-003877-87-CZOctapharma Pharmazeutika Prod.Ges.m.b.H64
进行中（未招募）
1 期
Clinical trial to confirm and expand information on absorption, distribution, elimination in the body, efficacy, tolerability and safety of a new drug in patients with impaired immune system.Primary immunodeficiencyEUCTR2013-003877-87-SKOctapharma Pharmazeutika Prod.Ges.m.b.H64
进行中（未招募）
1 期
Clinical trial to confirm and expand information on absorption, distribution, elimination in the body, efficacy, tolerability and safety of a new drug in patients with impaired immune system.Primary immunodeficiencyMedDRA version: 20.0Level: HLTClassification code 10036700Term: Primary immunodeficiency syndromesSystem Organ Class: 100000004870EUCTR2013-003877-87-PLOctapharma Pharmazeutika Prod.Ges.m.b.H64